The supplement is commonly used in areas where additional symptomatic support is needed for systemic imbalance that arises from nutritional deficiency. It is applied across domains involving certain distressing symptoms, contributing to improved comfort during periods of heightened symptoms. This supplement is relevant in contexts involving heightened systemic burden where supportive symptom management is appropriate. Common therapeutic areas include support for skeletal integrity, assistance with muscle function, and addressing nutritional insufficiency. The supplement is relevant in conditions characterized by periods of heightened symptoms, such as persistent tiredness or malaise that stem from low nutrient levels.

“This use provides supportive relief and helps maintain a sense of stability when lifestyle or environmental factors make obtaining the nutrient challenging.”

Quick Fact: Relief for Musculoskeletal Discomfort This supplement assists with maintaining functional stability for bone and muscle health, providing supportive relief when symptoms interfere with routine activities.

Regulatory References

1. MedlinePlus overview of Cholecalciferol

Official Eligibility Profile for Ostelin 800 (Dihydrotachysterol)

Official regulatory documents define patient eligibility for Ostelin 800 based on pre-existing clinical conditions, age, and physiological status.

Category	Official Regulatory Status Statement
Populations for whom use is allowed	Adults, Children, Infants, and Neonates are eligible for use in approved indications, provided no contraindications exist.
Populations for whom use is contraindicated	Patients with Hypercalcemia (abnormally high blood calcium), Hypervitaminosis D (excessive vitamin D), or known hypersensitivity to the medicine.
Age-related eligibility rules	Pediatric Use: Use is established, but dosage must be strictly individualized for neonates, infants, and children. Geriatric Use: Data are insufficient to determine if older adults respond differently, necessitating caution in dose selection.
Pregnancy and lactation eligibility status	Pregnancy: Historically assigned Category C. Use is conditional, only warranted if the potential benefit justifies the potential risk. Lactation: It is not known whether the medicine is excreted in human milk; caution should be exercised.
Eligibility-related restrictions	Use in patients with Renal Stones is conditional. Eligibility for patients with Renal Osteodystrophy who have Hyperphosphatemia depends on concurrently managing phosphorus levels with diet or binders.

---

Official Eligibility Statements:

• Use is prohibited where blood calcium or vitamin D levels are already elevated.
• Eligibility spans all age groups but mandates cautious and individualized use due to limited data in the elderly and the need for precision in children.

This structure reflects the regulatory priority of preventing elevated blood calcium while ensuring use is restricted to appropriate populations.

Interactions with other medicines and products

The official regulatory profile for Ostelin 800 (Dihydrotachysterol) defines interaction constraints primarily through its effect on mineral homeostasis and drug absorption. The documented statements are categorized by their severity and mechanism.

Prohibited and High-Risk Combinations

• Contraindicated Combinations: Co-administration with other Vitamin D Analogs or Pharmacologic Doses of Vitamin D is restricted due to the significant risk of additive toxicity, notably hypercalcemia and hyperphosphatemia.
• Cardiac Glycosides: Concomitant use with agents such as Digoxin is documented to increase the risk of severe cardiac arrhythmias. This is due to the potentiation of cardiac effects caused by elevated serum calcium levels.

Effects on Drug Exposure and Efficacy

• Thiazide Diuretics: These medicines have a documented pharmacodynamic reinforcing effect, substantially increasing the potential for hypercalcemia.
• Absorption Interference: Substances like Bile Acid Sequestrants (e.g., Cholestyramine) and Mineral Oil are officially documented to reduce the intestinal absorption of Dihydrotachysterol, leading to decreased serum concentration.
• Efficacy Reduction: Glucocorticoids (Corticosteroids) are documented in prescribing information to decrease the therapeutic efficacy of Dihydrotachysterol.

Food and Population Notes

• A high dietary intake of Vitamin D, Calcium, or Phosphorus is classified as an additive interaction that carries a risk of toxicity.
• Specific regulatory notes highlight increased interaction relevance in Hypoparathyroid Patients receiving Thiazides and for individuals with pre-existing arrhythmias co-administered with Cardiac Glycosides.

Mechanism of Action: The Vitamin D Receptor Cascade

Ostelin 800 (cholecalciferol) acts as a prodrug that undergoes two sequential hydroxylation steps, first in the liver and subsequently in the kidneys, to yield its active form, calcitriol (1,25-dihydroxyvitamin D3). Calcitriol functions as an agonist by binding to the Vitamin D Receptor (VDR), a nuclear receptor present in cells across multiple tissues, including the intestine, kidney, and bone.

Binding to the VDR initiates genomic modulation, altering the transcription of genes, most notably those responsible for calcium transport proteins. This mechanism substantially enhances the intestinal absorption of dietary calcium and phosphate and increases their reabsorption from the kidneys. The downstream physiological consequence is the elevation and maintenance of these minerals within reference concentration ranges, which supports the necessary conditions for bone matrix mineralization and modulates calcium signaling required for neuromuscular processes.

Official Administration and Dosing Guidelines

Dihydrotachysterol (Ostelin 800) is administered exclusively via the oral route. It is available in both oral solution (0.2 mg/mL) and oral tablet/capsule dosage forms. The medicine may be taken with or without food.

Treatment follows a distinct two-phase dosing regimen characterized by a short, high-dose initial course to establish stable mineral levels, followed by a long-term maintenance dose. The general frequency for both phases is once daily.

Labeled Dosing Regimens

The standard adult dosing schedule is structured around the patient’s clinical need, with dosages expressed in milligrams (mg):

• Initial Dose (Adult): 0.8 mg to 2.4 mg orally once daily for a period of several days. This higher dose is used for acute stabilization.
• Maintenance Dose (Adult): A reduced dose of 0.2 mg to 1.0 mg orally once daily is typical for long-term use. The average maintenance dose is 0.6 mg daily.

Procedural and Contextual Use

Therapy requires an adequate intake of calcium to support the drug's intended action of regulating blood calcium levels. Dose adjustments are not made frequently; instead, the labeling specifies that changes may be made at intervals of four to eight weeks after the stabilization period. Specific initial and maintenance regimens, also administered once daily, are available for pediatric patients (infants and children), distinguishing their use pattern from that of adults. The overall treatment pattern is designed to be long-term for chronic mineral imbalances.

Research evidence / Overview of Studies for Ostelin 800 (Dihydrotachysterol)

---

Evidence for Use in Hypoparathyroidism

Research has explored the use of Dihydrotachysterol in individuals diagnosed with an underactive parathyroid gland, a condition characterized by low blood calcium levels. The evidence base primarily consists of case reports, case series, and retrospective reviews, which were supported by some open-label comparative studies. Researchers were focused on monitoring and documenting Serum Calcium and Serum Phosphate concentrations, which are outcomes related to systemic or functional imbalance.

Studies monitored and described patterns in the measured changes of mineral levels, reporting how calcium levels evolved in the observed populations. Findings indicate that the agent was studied for its role in affecting calcium levels in the bloodstream. Much of the data used to contextualize this treatment is older and comes from non-randomized study designs, meaning evidence quality varies across studies.

---

Evidence for Use in Familial Hypophosphatemia

For the rare inherited bone disorder familial hypophosphatemia, research has explored Dihydrotachysterol, often as part of a combination regimen. The main study types available include observational studies, case reports, and small comparator trials, which were frequently conducted alongside phosphate supplements. Studies explored outcomes related to physical discomfort and assessed changes in bone health.

Findings describe patterns observed in the studies related to the measurement of phosphate levels. Reports documented observed changes in bone health metrics, such as the status of rickets in pediatric patients. The evidence is limited primarily because the rarity of the disease restricts the ability to conduct large-scale, prospective randomized trials, and its specific contribution is challenging to isolate when used with phosphate supplements.

---

Research Gaps and Uncertainties

A significant gap is the lack of comprehensive, contemporary comparative evidence from large-scale RCTs (Randomized Controlled Trials) that directly measure Dihydrotachysterol against newer generation Vitamin D analogs. Furthermore, sample sizes were modest or small in many of the trials for specialized uses, and follow-up durations were limited in certain key areas. These factors indicate that research is ongoing to fully establish long-term effects and explore findings across all studied populations.

Common questions about Ostelin 800 (FAQ)

---

Q: I have liver impairment. Is it safe for me to take this medicine?

According to official product information, Dihydrotachysterol must undergo a chemical change, or hydroxylation, that happens in the liver to become its main active form. For this reason, regulatory information suggests that discussing potential risks and monitoring needs with a healthcare professional may be appropriate for individuals with liver impairment.

---

Q: Will this medicine cause stomach discomfort or nausea?

Official regulatory documents indicate that nausea, vomiting, abdominal cramps, and constipation are symptoms that can be associated with elevated calcium levels (hypercalcemia). Experiencing these symptoms is described as a possible indicator of this condition. Official recommendations suggest informing a healthcare professional if these occur.

---

Q: Can I take antacids with this medication?

Regulatory warnings state that co-administration of this medication with antacids that contain magnesium or calcium should generally be avoided. This is due to the potential for interactions that could affect mineral levels in the body.

---

Q: Will this medicine affect my mood or sleep?

Official information regarding overdosage indicates that high calcium levels (hypercalcemia) may lead to central nervous system effects. These effects are described as including lethargy, depression, amnesia, disorientation, and hallucinations. Official recommendations suggest that a healthcare professional should be informed if these manifestations are observed.

---

Q: Will this medicine affect my blood pressure?

Official product information states that manifestations of overdosage may include effects on the cardiovascular system. Specifically, these effects can include high blood pressure (hypertension) or, in later stages, irregular or uneven heartbeats. This is linked to elevated calcium levels.

---

Q: Do I need a prescription to get this medicine?

Yes, Dihydrotachysterol is typically classified as a prescription-only medication in many regulatory jurisdictions. This status is generally given because of the need for precise dosing and clinical monitoring of mineral levels.

---

Q: Can this medication be used for the prophylactic prevention of vitamin D deficiency?

Official medical sources describe Dihydrotachysterol as being indicated for the prevention and treatment of vitamin D deficiency states. It is also indicated to manage low calcium levels (hypocalcemia) that are related to an underactive parathyroid gland.

How to Store and Dispose of Ostelin 800?

The official storage and disposal guidelines for Ostelin 800 (colecalciferol) are defined by government regulatory documents to maintain the product's quality and ensure safe disposal.

Requirement	Official Regulatory Statement
Storage Temperature	Store below 25 C.
Protection	Must be kept in the original package (outer carton/blister) to protect from light and moisture.
Stability	Shelf life is typically documented as 24 to 36 months when stored correctly.
Container Integrity	Store in the original package; do not use if the cap seal is missing or broken.

Disposal instructions require that any unused product or waste material be handled and eliminated strictly in accordance with local pharmaceutical waste management regulations. The medicine must not be discarded in general household waste or flushed down the toilet.